MAHE establishes ICMR–MAHE Centre for Advanced Research with Rs 12.84 Cr ICMR grant

IMT News Desk
IMT News Desk
· 3 min read

The centre will develop and assess a Multifaceted Comprehensive Appropriate Care Package (MCACP) that incorporates palliative care principles within critical care environments

The Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University, inaugurated the ICMR–MAHE Centre for Advanced Research (CAR) at the Manipal Hospice and Respite Centre (MHRC), following the award of a Rs 12.84 crore grant from the Indian Council of Medical Research (ICMR). The Centre is led by Dr Naveen Salins, Professor and Head of the Department of Palliative Medicine and Supportive Care at Kasturba Medical College (KMC), Manipal, as Principal Investigator, with Dr Arun Ghoshal, Assistant Professor, serving as Co-Principal Investigator.

The inauguration was honoured by Dr Ashoo Grover, Scientist G and Head, Division of Delivery Research, ICMR, who was the Chief Guest, and Dr Roopa Shivashankar, Scientist E (Medical), Division of Delivery Research, ICMR, as the Guest of Honour. The event was presided over by Dr HS Ballal, Pro-Chancellor, MAHE, and organised by Dr Sharath K Rao, Pro-Vice Chancellor (Health Sciences), MAHE. Dr Anil K Bhat, Dean of KMC Manipal, and Dr Cherian Varghese, Director of the Prasanna School of Public Health, participated in this inauguration. In his address, Dr Ballal emphasised that the partnership between ICMR and MAHE represents “the highest level of national recognition for MAHE’s research culture” and reflects the University’s enduring commitment to “science that heals and research that transforms.” Dr Sharath K Rao outlined the roadmap for health research at MAHE.

The Centre for Advanced Research (CAR) aims to fill a vital gap in India’s healthcare system—the need for ethical, compassionate, and evidence-based care for patients with advanced and terminal illnesses admitted to Intensive Care Units (ICUs). The centre will develop and assess a Multifaceted Comprehensive Appropriate Care Package (MCACP) that incorporates palliative care principles within critical care environments. This initiative builds on MAHE’s pioneering BLUE MAPLE framework, created and implemented at Kasturba Hospital and KMC Manipal, which has shaped national end-of-life care standards. The CAR will now expand this work nationwide, establishing a multi-centre collaborative network comprising ten clinical centres and seven technical partners.  

The Centre’s work spans multiple disciplines—medicine, nursing, bioethics, health economics, law, and public health—reflecting MAHE’s belief in the “One Health–One Humanity” approach to research and innovation. By co-developing and testing a nationally scalable model of appropriate care for ICU patients with advanced illness, the CAR aims to influence policy, improve health-system responsiveness, and generate evidence that aligns with the UN Sustainable Development Goals (SDGs).

MAHE has a longstanding legacy of promoting research, innovation, and translational impact. The establishment of the ICMR–MAHE CAR strengthens MAHE’s position as a leading contributor to India’s health-research ecosystem. It reaffirms its mission to integrate science, ethics, and empathy in healthcare delivery. The Centre for Advanced Research will serve as a national and global reference point for ICU and palliative-care research, setting new benchmarks for interdisciplinary and implementation science in India.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk